Jump to content

Zometa every 3 months just as effective as monthly Zometa

Paul Edwards

Recommended Posts

The results of a large, randomized clinical trial of the use of zoledronic acid (Zometa) were presented at the recent annual meeting of the American Society of Clinical Oncology (ASCO).


In this trial the researchers set out to test whether giving zoledronic acid every 3 months would be just as effective (i.e., “non-inferior”) at reducing bone pain and skeletal-related events (SREs) in patients with bone metastases as giving it according to the standard recommended regimen (once a month) specified in the product’s prescribing information.


They found that zoledronic acid administered every 3 months was just as effective to zoledronic acid administered monthly for 24 months in breast cancer, prostate cancer and multiple myeloma patients.




Dr Jeffrey J. Kirshner identified this trial as one of the 10 practice-changing presentations from this year's ASCO annual meeting and said this less frequent dosing of zoledronic acid “will be less expensive and result in fewer visits for our patients and probably an improved quality of life.”



References (click on the link to read)

Article in the “New” Prostate Cancer Infolink

Abstract of the trial presented at ASCO

Comments by Dr Kirshner 

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...